CorVel Corporation (CRVL)
NASDAQHealth CareInsurance - BrokersSnapshot 2026-09-04
$68.23-0.66%
Close 2026-09-04 · 1-day change
NASDAQHealth CareInsurance - BrokersSnapshot 2026-09-04
QuarterlyIQ Insights · CRVL
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $68 the market pays 30× p/e — above the 23× p/e peer median but in line with its own 30× history. That premium reflects a durable franchise our peer-anchored $57 fair value understates; treat the 'expensive vs peers' read with medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcfe | 12M | $89.63 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $94.66 | — | — | Hist. CAGR | high |
| graham number | 12M | $20.13 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $45.98 | 12.7 | 3.23 | TTM | high |
| Peer P/FCF | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 81% over what the business is worth with no growth; closing that gap needs roughly 29.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $1.95/sh owner earnings.
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2026-Q1, 2026-Q2, 2026-Q3, 2027-Q1
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $48.24 |
| 21.6 |
| 2.23 |
| TTM |
| high |
| Peer P/E | 12M | $51.40 | 22.9 | 2.24 | TTM | high |
| Peer P/S | 12M | $72.65 | 3.8 | 19.32 | TTM | high |
| residual income | 12M | $14.47 | — | — | TTM | high |
| Own P/E history | 12M | $66.24 | 29.5 | 2.24 | TTM | high |
| triangulated | 12M | $52.30 | 22.9 | 2.28 | Triangulated | high |
| Peer P/FCF | 3Y | $73.37 | 21.6 | 3.40 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $94.79 | 3.8 | 25.20 | Hist. CAGR(prov.) | medium |
| Peer P/FCF | 5Y | $97.03 | 21.6 | 4.50 | Hist. CAGR(prov.) | medium |
| Peer P/S | 5Y | $113.18 | 3.8 | 30.09 | Hist. CAGR(prov.) | medium |